MX2022012969A - Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos. - Google Patents

Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.

Info

Publication number
MX2022012969A
MX2022012969A MX2022012969A MX2022012969A MX2022012969A MX 2022012969 A MX2022012969 A MX 2022012969A MX 2022012969 A MX2022012969 A MX 2022012969A MX 2022012969 A MX2022012969 A MX 2022012969A MX 2022012969 A MX2022012969 A MX 2022012969A
Authority
MX
Mexico
Prior art keywords
methods
binding protein
lipid binding
acute conditions
treating acute
Prior art date
Application number
MX2022012969A
Other languages
English (en)
Spanish (es)
Inventor
Ronald Barbaras
Cyrille Tupin
Constance Peyrottes
Original Assignee
Abionyx Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abionyx Pharma Sa filed Critical Abionyx Pharma Sa
Publication of MX2022012969A publication Critical patent/MX2022012969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2022012969A 2020-04-16 2021-04-15 Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos. MX2022012969A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063011055P 2020-04-16 2020-04-16
US202063092070P 2020-10-15 2020-10-15
US202063121640P 2020-12-04 2020-12-04
PCT/IB2021/000283 WO2021209823A1 (en) 2020-04-16 2021-04-15 Methods for treating acute conditions using lipid binding protein- based complexes

Publications (1)

Publication Number Publication Date
MX2022012969A true MX2022012969A (es) 2022-11-09

Family

ID=76197484

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012969A MX2022012969A (es) 2020-04-16 2021-04-15 Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.

Country Status (10)

Country Link
US (1) US20240033322A1 (https=)
EP (1) EP4135747A1 (https=)
JP (1) JP2023522889A (https=)
KR (1) KR20230004605A (https=)
CN (1) CN115427064A (https=)
AU (1) AU2021256086A1 (https=)
CA (1) CA3177243A1 (https=)
IL (1) IL297336A (https=)
MX (1) MX2022012969A (https=)
WO (1) WO2021209823A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11752163B2 (en) 2020-04-16 2023-09-12 Abionyx Pharma Sa CER-001 therapy for treating kidney disease
MX2023012223A (es) * 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
CN119317440A (zh) * 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
JP2025519606A (ja) * 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL317448A (en) * 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
IL322074A (en) * 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
CN116893215A (zh) * 2023-03-17 2023-10-17 安徽省立医院(中国科学技术大学附属第一医院) 一种用于监测car-t治疗之后crs进程的临床标志物及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
CA2185450A1 (en) 1994-03-22 1995-09-28 Patrick Tso Eating suppressant peptides
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
DE60117781T2 (de) 2000-04-21 2006-11-23 Amgen Inc., Thousand Oaks Peptidderivate des apolipoproteins-a1/aii
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
BR0115257A (pt) 2000-11-10 2003-08-12 Proteopharma Aps Análogos de apolipoproteìna
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
DE60226881D1 (de) 2001-08-20 2008-07-10 Zlb Bioplasma Ag High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
JP2006507223A (ja) 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
EP1545576A2 (en) 2002-07-30 2005-06-29 Esperion Therapeutics Inc. Methods of using non-human animal apoliprotein a-i protein
TWI433693B (zh) 2003-02-14 2014-04-11 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
KR101185609B1 (ko) 2004-07-16 2012-09-24 트러스티즈 오브 터프츠 칼리지 아포리포단백질 ａ１ 미메틱 및 이의 용도
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP1917278A2 (en) 2005-08-26 2008-05-07 Cerenis Therapeutics Holding SA Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
US20080293102A1 (en) 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
WO2009055538A1 (en) 2007-10-23 2009-04-30 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
JP5719783B2 (ja) 2009-02-16 2015-05-20 セレニス セラピューティクス ホールディング エスアー アポリポタンパクａ−ｉ模倣物
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
EP3842443B1 (en) 2013-03-15 2025-02-19 Cerenis Therapeutics Holding SA Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2018029505A1 (en) * 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
FR3100715B1 (fr) * 2019-09-12 2023-09-29 Francais Du Sang Ets Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte

Also Published As

Publication number Publication date
IL297336A (en) 2022-12-01
US20240033322A1 (en) 2024-02-01
CN115427064A (zh) 2022-12-02
CA3177243A1 (en) 2021-10-21
EP4135747A1 (en) 2023-02-22
JP2023522889A (ja) 2023-06-01
WO2021209823A1 (en) 2021-10-21
AU2021256086A1 (en) 2022-12-15
KR20230004605A (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
MX2022012969A (es) Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
JOP20210129A1 (ar) مثبطات apol1 وطرق استخدامها
CL2021002212A1 (es) Tratamiento de lesión renal
EP4389142A3 (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
MX2019002064A (es) Anticuerpos de anti-tim-3.
JOP20210314A1 (ar) Tigit وجزيئات ربط pd-1/tigit
MX2022000310A (es) Inhibidores de proteina bcl-2.
EA200802365A1 (ru) Аминометилзамещенные тетрациклиновые соединения
RU2015102596A (ru) Произвольный доступ и сигнализация долгосрочных опорных картинок при кодировании видео
ZA202201437B (en) Compositions and methods for treating inflammasome related diseases or conditions
PH12020500664A1 (en) C3-binding agents and methods of use thereof
EP4131800A3 (en) Communication devices and methods for signaling in non-terrestrial networks
EP4389209A3 (en) Fecal microbiota composition, for use in reducing treatment-induced inflammation
MX2023005180A (es) Compuestos de union a il-2r\03b2?c y usos de estos.
MX2019008545A (es) Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa.
WO2022115709A3 (en) Methods and composition for treating metabolic syndrome
MX2024013871A (es) Agentes aglutinantes 5t4 y usos de los mismos
MX2024015277A (es) Metodos para tratar afecciones agudas utilizando complejos basados en proteinas de union a lipidos
MX2024006205A (es) Composiciones que comprenden agentes de unión multiespecíficos potenciados para una respuesta inmunitaria.
WO2021231803A3 (en) Binding molecules for covid-19 treatment
EP4329306A4 (en) Methods and devices for processing a code stream, terminal device and storage medium